Navigation Links
Amira Announces AM103 and AM803 Patent Grant in the United Kingdom
Date:7/13/2010

SAN DIEGO, July 13 /PRNewswire/ -- Amira Pharmaceuticals, Inc. today announced that the U.K. Intellectual Property Office has granted patent number GB2431927, titled, "5-Lipoxygenase Activating Protein (FLAP) Inhibitors," which includes coverage of Amira's AM103 and AM803 FLAP inhibitors for the treatment of respiratory disorders.

In January 2008, Amira and GlaxoSmithKline (GSK) entered into a worldwide exclusive agreement allowing GSK to develop, manufacture and commercialize specified FLAP inhibitors for the treatment of respiratory and cardiovascular disease.  AM803 was added to the license agreement later in 2008.  GSK is currently conducting Phase 2 clinical trials in respiratory disorders with an Amira-licensed FLAP inhibitor.

"Amira continues to be successful in obtaining patent coverage for compounds being advanced in clinical trials," said John Hutchinson, Ph.D., Vice President of Chemistry.  "This patent covering both AM103 and AM803 is the third issued this year, following two patents related to our DP2 receptor antagonists granted by the United Kingdom."  Bob Baltera, Chief Executive Officer of Amira, added, "This patent relates to some of the first compounds developed by Amira.  It reflects our ongoing objective to secure strong patent protection around each of our development programs."

The newly granted claims cover novel inhibitors of the FLAP protein.  The patent also discloses uses of FLAP inhibitors for the treatment of inflammatory diseases such as asthma, cardiovascular disease, dermatological disorders and ocular diseases.

About Amira

Founded in 2005 and headquartered in San Diego, Amira Pharmaceuticals is a small molecule pharmaceutical company focused on the discovery and early development of new drugs to treat inflammatory disease.  Our discovery team is building on unparalleled insights into bioactive lipid pathways and complex signaling processes controlling many conditions including asthma, chronic obstructive pulmonary disease, cardiovascular and fibrotic diseases.  Amira has a partnership with GlaxoSmithKline for the development of FLAP (5-lipoxygenase activating protein) inhibitors in respiratory and cardiovascular disease.

Amira combines the rigor of a big pharmaceutical company with the ingenuity and energy of a small company, creating an environment for efficient development of novel compounds and effective pre-clinical and clinical program decisions.  Its scientific founders have successfully worked together for more than a decade and were pivotal in the discovery of a number of inflammatory drugs, including Singulair®.  The drug hunters at Amira are now actively leveraging their history of success to create high-value compounds for the future.  For more information, visit www.amirapharm.com.


'/>"/>
SOURCE Amira Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Amira Announces Second DP2 Antagonist Patent Grant in the United Kingdom
2. Anti-Fibrotic Data from Amira Pharmaceuticals LPA1 Receptor Antagonist Program Published in the British Journal of Pharmacology
3. Amira Pharmaceuticals Announces Efficacy of LPA1 Antagonist in a Preclinical Model of Scleroderma
4. Amira Pharmaceuticals Announces Initial Positive Phase 1 Clinical Data for AM461, A Back-Up to Amiras Lead DP2 Antagonist, AM211
5. Amira Pharmaceuticals Submits IND for Second DP2 Antagonist, AM461
6. Hanger Orthopedic Group, Inc. Announces Second Quarter 2010 Earnings Release Conference Call
7. K-V Pharmaceutical Announces Resubmission to New Drug Application for Gestiva™
8. Rcadia Announces Five COR Analyzer® Studies to be Presented at SCCT Annual Scientific Meeting
9. Medical Alarm Concepts™ Announces Roll-Out of the MediPendant™ at Albertsons
10. Biovista Announces the Appointment of Clifford H. Farrah to its Advisory Board
11. Telik Announces Publication of Review Focused on the Inhibition of the Enzyme GSTP1-1 as a Target for New Cancer Treatments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... Research and Markets has announced the addition of the "Global ... ... very strong with a total of 97 drug candidates. Pharma giant such ... involved in the development of the IPF therapeutics. The IPF pipeline comprised ... 15 are in Phase II stage, 12 are in Phase I stage, ...
(Date:3/24/2017)... India , March 24, 2017 ... of the industry including definitions, classifications, applications and industry ... the international market including development history, competitive landscape analysis, ... ... Ampoules industry spread across 105 pages providing 10 company ...
(Date:3/24/2017)... , March 24, 2017  GenomeDx Biosciences today ... Information Database) and Decipher® Prostate Cancer Classifier tests will ... Association of Urology (EAU) Congress held March 24 to ... The Annual EAU Congress is Europe,s ... comprehensive research in the urological field. The ...
Breaking Medicine Technology:
(Date:3/24/2017)... ... March 24, 2017 , ... ... countries to hospitals in the United States, it’s a threat that is constantly ... obstacles facing infection prevention and offers strategies for the healthcare community to help ...
(Date:3/24/2017)... ... ... According to a new study by NCPA Senior Fellow John R. Graham, "the ... has directed the CBO to follow. The CBO itself previously recognized Obamacare would kill ... a reduction in employer-based coverage due to the GOP reform, which is not plausible. ...
(Date:3/24/2017)... ... March 24, 2017 , ... ... and related services to families and business owners across eastern Michigan, is connecting ... regional families struggling with financial difficulties. , The Oxford/Orion FISH Food Pantry works ...
(Date:3/24/2017)... ... March 24, 2017 , ... As the standards ... a communications platform that positions them as the go-to thought leader in all ... online publication as an always-on, always-fresh news, views and advocacy engine, called ONS ...
(Date:3/24/2017)... ... March 24, 2017 , ... The law firm of ... is pleased to announce Westchester resident Lauren C. Enea has joined the firm as ... firm, will concentrate her practice in elder law, Medicaid planning and applications, and Wills, ...
Breaking Medicine News(10 mins):